Skip to content

Studying the effect of vibrating gloves on reducing symptoms of Parkinson's disease

Empowering Parkinson's patients with vibrational Coordinated Reset method

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250922067329N1
Enrollment
6
Registered
2025-10-21
Start date
2025-10-23
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Parkinson’s. Parkinson's disease

Interventions

Intervention 1: Intervention group: A group of 3 patients who have been provided with the original gloves.Then, after a month of using the original glove, they receive the sham glove.We do not have a

Sponsors

The University of Tehran
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients participating in this trial are between 45 and 85 years old. While taking the medication, Parkinson's disease was diagnosed with Hoehn and Yahr stage 2 to 4 criteria. Patients must communicate clearly with staff and speak Persian.

Exclusion criteria

Exclusion criteria: Patients cannot have dopamine dis regulation syndrome or the presence of other neurological diseases such as major depression, dementia, attention deficit disorder, psychosis, or essential tremor. Patients cannot have a history of epilepsy, traumatic brain injury, or brain surgery. Patients cannot have severe sensory abnormalities of the fingertips, such as vibratory urticaria. They were excluded from the study if they were currently using psychotropic or narcotic medications or taking medications that affect brain function that would alter recorded EEG activity (such as anticonvulsant, ADHD, depression, or anxiety medications). Patients who are pregnant, lactating, or trying to become pregnant during the study period will be excluded from the study. Also, according to the selected TUG task, patients should not have a history of multiple sclerosis (MS), Alzheimer's, hip fracture, total knee or hip replacement surgery, Huntington's disease, and a history of stroke.

Design outcomes

Primary

MeasureTime frame
EEG connectivity. Timepoint: We have an EEG data acquisition as initial data from the patient, 14 days later the glove is delivered and data is collected on the same day, the next day-15th day data is collected to examine the short-term effect, then 2 weeks later, 14 days after delivery, we will have another data collection session, and finally 30 days after delivery, we will have another session. Then the Sham glove will be delivered and 3 data collection sessions will be taken in the first month, the middle of the month, and the end of the month, which will ultimately have 8 data collection sessions. Method of measurement: EEG data acquisition is performed with the help of a portable device at the National Brain Mapping Laboratory. For each patient, two weeks before the start of the study, a 10-minute EEG is taken during a standard cognitive TUG task with a vibrating glove.Then, after two weeks, data collection is repeated. First, 10 minutes without stimulation are taken before data collection, and then the glove is worn by the patient and 10 minutes of EEG data collection is performed with the vibrating glove stimulation during the TUG task. Then, data is collected from the patient again for 10 minutes without gloves during the TUG task. This will be a data collection session.The next day, data collection is also collected in the same way. Then the glove will be provided to the patient. Then, 2 weeks after the glove is delivered, we will have an EEG data collection session on the same day. Finally, we will have a data collection session 2 weeks later. In this way, in the first month, we will have 4 half-hour EEG data collection sessions from the patient. Then, we perform the same procedure in the second month with the Sham glove, which will be a total of 9 sessions in 2 months and 2 weeks, collecting data from the patient.;UPDRS-III. Timepoint: Before each EEG session, the patient's ,UPDRS-III is taken once, for a total of 8 times. Method of measurement: This var

Secondary

MeasureTime frame
Comparison of EEG connectivity before and after using with gloves. Timepoint: Once the data is collected, a meaningful comparison analysis is performed. Method of measurement: By comparing the brain connectivity matrix before and after the intervention, connectivity should be reduced on average.;Comparison of UPDRS-III score before and after intervention with effect size criterion and t-test statistical test. Timepoint: Once after data collection, every 7 data collection times are examined with the pre-intervention state for these statistical criteria. Method of measurement: The UPDRS-III score before and after the intervention is examined using t-test and Anova-test statistical tests to determine the effect size of the intervention.;Comparison of PDQ-39 scores before and after intervention using t-test and Anova-test statistical tests. Timepoint: Once after data collection, every 7 data collection times are examined with the pre-intervention state for these statistical criteria. Method of measurement: The PDQ-39 score before and after the intervention is examined using t-test and Anova-test statistical tests to determine the effect size of the intervention.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAboozar Moradi

The University of Tehran

amoradi1981@ut.ac.ir+98 21 2610 1508

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026